-
ʻO Dabrafenib
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) ʻO Dabrafenib -
Aprocitentan
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Aprocitentan -
Tirzepatide
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Tirzepatide ʻO ka maʻi diabetes type 2, hoʻemi i ke kaumaha Eli Lilly Jan.05,2036 -
Semaglutide
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Semaglutide ʻO ka maʻi diabetes type2, hoʻemi i ke kaumaha Novo Nordisk Dek.05,2031 -
Oteseconazole
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Oteseconazole E hoemi i ka helu o ka candidiasis vulvovaginal hou
MycoviaPharmaceuticals Apr.22,2031 -
Finerenone
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Finerenone ʻO Nephropathy maʻi maʻi Bayer Apr.12,2029 -
Capivasertib
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Capivasertib ka maʻi ʻaʻai umauma AstraZeneca Mar.10.2030 -
Resmetirom
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Resmetirom NASH ʻO Roche Sep.12,2026 -
ʻO Darolutamide
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) ʻO Darolutamide lapaʻau maʻi maʻi prostatic Bayer Mar. 25,2033 -
Upadacitinib
Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika) Upadacitinib ʻO ka Dermatitis Atopic ABBVIE INC Dek.01,2030